LEADER 06345nam 22013333a 450 001 9910367750303321 005 20250203235429.0 010 $a9783039215737 010 $a3039215736 024 8 $a10.3390/books978-3-03921-573-7 035 $a(CKB)4100000010106214 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/52765 035 $a(ScCtBLL)a7a8ca01-40f3-409f-8ced-77dac6b912b6 035 $a(OCoLC)1163812839 035 $a(oapen)doab52765 035 $a(EXLCZ)994100000010106214 100 $a20250203i20192019 uu 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMarine Anti-inflammatory Agents$fJavier Avila-Román, Elena Talero 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 electronic resource (248 p.) 311 08$a9783039215720 311 08$a3039215728 330 $aAcute inflammation is a highly regulated process, and its dysregulation can lead to the development of a chronic inflammatory state which is believed to play a main role in the pathogenesis of many diseases, including cancer. In recent years, the need to find new anti-inflammatory molecules has raised the scientific community´s interest for marine natural products. In this regard, the marine environment represents a source for isolating a wealth of bioactive compounds. In this Special Issue, the reported products have been obtained from microalgae, sea cucumber, octopus, squid, red alga-derived fungus, cnidarians, hard-shelled mussel, and sponges. This Special Issue of Marine Drugs covers both the in vitro and in vivo studies of marine agents with anti-inflammatory activities, in addition to clinical trials conducted in humans. Among the bioactive molecules reported in the papers are lipid compounds, such as glycolipids, which, for the first time, demonstrated their preventive effects in an inflammatory model of skin hyperplasia. In addition, beneficial effects of the carotenoid fucoxanthin were shown in the same model of skin hyperplasia, in UVB-induced damage and in a model of inflammatory pain. Moreover, frondanol, a lipid extract from Cucumaria frondosa, attenuated inflammation in an acute colitis model. Another paper evaluated the fatty acid compositions of lipid extracts from some common seafood organisms, reporting the highest level of omega 3 polyunsaturated fatty acids and the highest anti-inflammatory activity in the extracts from octopus and squid byproducts. Additionally, the anti-inflammatory effects of other marine compounds have been reported, including hirsutanol A, a sesquiterpene from the red alga-derived marine fungus Chondrostereum sp. NTOU4196, two zoanthamine alkaloids from the zoantharian Zoanthus cf. pulchellus, an ?-D-glucan from the hard-shelled mussel (Mytilus coruscus), and the polyphenol pyrogallol-phloroglucinol-6,6-bieckol from an edible marine brown alga.Finally, this Special Issue is supplemented by three reviews focused on the occurrence of prostaglandins in the marine environment and their anti-inflammatory role; fish lipid emulsions used to improve patient outcomes in an inflammatory environment, such as postoperative; and the chemically induced production of compounds with anti-inflammatory activity from microalgae. 606 $aMedicine and Nursing$2bicssc 610 $aTropical Eastern Pacific 610 $aZoanthus pulchellus 610 $acritical illness 610 $azoanthamine 610 $aSPR analysis 610 $adendritic cells 610 $aendothelial cell death 610 $aT cell differentiation 610 $aseafood waste 610 $amicroalgae 610 $apyrogallol-phloroglucinol-6 610 $aNRLP3 610 $aTHP-1 macrophages 610 $afucoxanthin 610 $aphoto-protection 610 $acytokine 610 $athromboxane 610 $aIsochrysis galbana 610 $afish oil 610 $aphotoprotection 610 $afunctional ingredients 610 $arosmarinic acid 610 $aMAPK 610 $amarine invertebrates 610 $apoor blood circulation 610 $aanti-inflammatory activity 610 $aeicosapentaenoic acid 610 $aanti-oxidative 610 $amacroalgae 610 $acolon inflammation 610 $aMGDG 610 $aTLR4 610 $a6-bieckol 610 $apolyunsaturated fatty acid 610 $amatrix metalloproteinases-9 (MMP-9) 610 $aacute sickness behavior 610 $aUVB 610 $aeicosanoid 610 $aclavulones 610 $acarotenoids 610 $adenervation 610 $apolyunsaturated fatty acids 610 $askin 610 $aepidermal hyperplasia 610 $aGeodia barretti 610 $aomega-3 610 $aparenteral nutrition 610 $ainflammation 610 $aultraviolet B 610 $adocosahexaenoic acid 610 $asignal transducer and activator of transcription 3 (STAT3) 610 $aanti-inflammatory 610 $azoantharia 610 $avascular smooth muscle cell proliferation and migration 610 $abioactive molecules 610 $apolysaccharides 610 $alipopolysaccharide (LPS) 610 $aglycolipids 610 $aDSS colitis 610 $apunaglandins 610 $amarine nutraceuticals 610 $amarine vertebrates 610 $aphlorotannins 610 $aacute lung injury (ALI) 610 $aNF-?B 610 $adiatoms 610 $ainterleukin (IL) 610 $ainflammasome 610 $aFrondanol 610 $aCucumaria frondosa 610 $aprostaglandins 610 $aEcklonia cava 610 $a6-bromoindole 610 $aNO inhibition 610 $asurgery 615 7$aMedicine and Nursing 700 $aAvila-Román$b Javier$01787403 702 $aTalero$b Elena 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910367750303321 996 $aMarine Anti-inflammatory Agents$94320831 997 $aUNINA LEADER 04323nam 22010933a 450 001 9910367751403321 005 20250203235433.0 010 $a9783039215836 010 $a3039215833 024 8 $a10.3390/books978-3-03921-583-6 035 $a(CKB)4100000010106203 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/53824 035 $a(ScCtBLL)5fc187e9-5edd-4bb3-99d9-ba19ad58202b 035 $a(OCoLC)1163845405 035 $a(oapen)doab53824 035 $a(EXLCZ)994100000010106203 100 $a20250203i20192019 uu 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMolecular Basis of Cardiovascular Diseases : $eImplications of Natriuretic Peptides /$fSperanza Rubattu, Massimo Volpe 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 electronic resource (212 p.) 311 08$a9783039215829 311 08$a3039215825 330 $aThe natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological regulation of blood pressure, and of heart and kidney functions. NPs have also been implicated in the pathogenesis of several cardiovascular diseases (CVDs), including hypertension, atherosclerosis, heart failure, and stroke. A fine comprehension of the molecular mechanisms dependent from NPs and underlying the promotion of cardiovascular damage has contributed to improve our understanding of the molecular basis of all major CVDs. Finally, the opportunity to target NPs in order to develop new therapeutic tools for a better treatment of CVDs has been developed over the years. The current Special Issue of the Journal covers all major aspects of the molecular implications of NPs in physiology and pathology of the cardiovascular system, including NP-based therapeutic approaches. 606 $aMedicine$2bicssc 610 $apostmortem biochemistry 610 $amedulla 610 $aanimal models 610 $aremodeling 610 $aBNP 610 $aPCSK9 610 $aguanylyl cyclase/natriuretic peptide receptor-A 610 $acardiorenal syndrome 610 $aforensic medicine 610 $apreserved ejection fraction 610 $akidney 610 $arenin-angiotensin-aldosterone system 610 $aatrial fibrillation 610 $avasopressor 610 $acongestive heart failure 610 $aatrial natriuretic peptide 610 $agene-knockout 610 $aobesity 610 $aheart failure 610 $aangiogenesis 610 $aadipose tissue 610 $avascular 610 $aLDL receptor 610 $ametabolic syndrome 610 $alinkage analysis 610 $acardiometabolic disease 610 $acardiomyocyte 610 $acardiac dysfunction 610 $acardiac hypertrophy 610 $ainsulin 610 $alipid metabolism 610 $acGMP 610 $aIdiopathic Pulmonary Arterial Hypertension (IPAH) 610 $aNatriuretic Peptide Clearance Receptor (NPR-C) signaling 610 $agene-duplication 610 $arenin?angiotensin system 610 $anatriuretic peptides 610 $aangiotensin receptor?neprilysin inhibitor 610 $acardiac remodelling 610 $aARNi 610 $aNT-proBNP 610 $ainflammation 610 $apulmonary arterial hypertension 610 $avascular homeostasis 610 $aendothelial cell 610 $aAtrial Natriuretic peptide 610 $anatriuretic peptide 610 $avasodilator 610 $astroke 610 $agenetic variants 610 $aarterial hypertension 610 $afibroblast 610 $aMANP 610 $ahypertension 610 $aguanylyl cyclase receptor A 615 7$aMedicine 700 $aRubattu$b Speranza$01324890 702 $aVolpe$b Massimo 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910367751403321 996 $aMolecular Basis of Cardiovascular Diseases$94318014 997 $aUNINA